Research Topics
Genomes and Genes | Andrew M ScottSummaryAffiliation: Ludwig Institute for Cancer Research Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignanciesAndrew M Scott
Centre for PET, Ludwig Institute for Cancer Research and Ludwig Oncology Unit, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
EJNMMI Res 2:31. 2012..abstract:..
Antibody therapy of cancerAndrew M Scott
Ludwig Institute for Cancer Research University of Melbourne and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australia
Nat Rev Cancer 12:278-87. 2012..This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials...
A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptakeAndrew M Scott
Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Melbourne, Victoria, Australia
Clin Cancer Res 11:4810-7. 2005..To determine the in vivo characteristics of huA33, a CDR-grafted humanized antibody against the A33 antigen, we have conducted an open-label, dose escalation, biopsy-based phase I trial of huA33 in patients with colorectal carcinoma...
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsAndrew M Scott
Ludwig Institute for Cancer Research, 143 165 Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
Proc Natl Acad Sci U S A 104:4071-6. 2007..These in vitro and in vivo characteristics of ch806 distinguish it from all other antibodies targeting EGFR...
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigenAndrew M Scott
Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Australia
Clin Cancer Res 13:3286-92. 2007..We report a first-in-man trial of a humanized antibody (hu3S193) against the Le(y) antigen...
Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective studyAndrew M Scott
Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Melbourne, Victoria 3084, Australia
Eur J Nucl Med Mol Imaging 36:347-53. 2009..Positron emission tomography (PET) was evaluated in low-grade non-Hodgkin lymphoma (NHL) to determine its impact on staging and management and to compare PET and gallium scans...
PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective studyAndrew M Scott
Department of Medicine, University of Melbourne, Melbourne, Australia
J Nucl Med 49:1593-600. 2008..Secondary aims were to determine the incremental staging information provided by PET and to document the effect of PET on treatment outcomes...
PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective studyAndrew M Scott
Centre for PET, Austin Hospital, Melbourne, Australia
J Nucl Med 49:1451-7. 2008..The aims of our study were to examine the impact of PET in changing management in patients with proven or suspected colorectal cancer recurrence and to assess the impact of management change on disease-free survival...
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapyMarcus P Kelly
Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
Prostate 69:92-104. 2009..The ability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 and docetaxel chemotherapy to enhance the efficacy of RIT was also assessed in vivo...
Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478Fook T Lee
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
Clin Cancer Res 11:7080s-7086s. 2005..Further investigations of dosing regimens using EGFR tyrosine kinase inhibitors and radioimmunotherapy in the treatment of EGFR expressing tumors are warranted...
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapyMarcus P Kelly
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
Clin Cancer Res 13:5604s-5612s. 2007..Therefore, we have investigated the efficacy of the alpha-particle-emitting bismuth-213 (213Bi) radioimmunotherapy using the humanized anti-Lewis Y (Ley) monoclonal antibody humanized 3S193 (hu3S193)...
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activityRushika M Perera
Ludwig Institute for Cancer Research, Melbourne Branch, Tumor Targeting Program, Austin Hospital, Heidelberg, Victoria, Australia
Clin Cancer Res 11:6390-9. 2005..Thus, mAb 806 can synergize with other EGFR-specific antibodies thereby providing a rationale for its translation into the clinic...
Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody constructMarcus P Kelly
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
Cancer Biother Radiopharm 23:411-23. 2008..However, limited in vitro stability and high renal localization of radiolabeled constructs were observed, which, despite the observed tumor targeting of the hu3S193 multimer, most likely preclude its use in RIT and imaging modalities...
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806Hui K Gan
Oncogenic Signalling Laboratory, Ludwig Institute of Cancer Research, Austin Hospital, Level 6, Harold Stokes Building, Studley Road, Heidelberg, Victoria 3084, Australia
J Biol Chem 282:2840-50. 2007..This information was used to optimize the therapeutic synergy between mAb 806 and AG1478 in a xenograft model...
Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibodyRushika M Perera
Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
Neoplasia 9:1099-110. 2007..These results highlight the potential use of mAb 806 for generation of conjugates suitable for diagnostic and therapeutic use in patients with EGFR-positive malignancies...
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptorTerrance G Johns
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg 3084, Australia
J Biol Chem 279:30375-84. 2004..Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity...
Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806Fook T Lee
Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
J Nucl Med 51:967-72. 2010..The aim of this study was to develop a PET-based method for detecting the constitutively active mutant de2-7 EGFR, which is associated with disease progression and resistance to chemotherapy and radiotherapy in glioma...
Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scansJoe H Chang
Radiation Oncology Centre, Austin Health, Victoria, Australia
Int J Radiat Oncol Biol Phys 83:e691-6. 2012..To demonstrate the technical feasibility of intensity modulated radiation therapy (IMRT) dose painting using (11)C-choline positron emission tomography PET scans in patients with localized prostate cancer...
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinomaIan D Davis
Ludwig Institute for Cancer Research, Victoria, Australia
Cancer Immun 7:14. 2007..No antitumour responses were observed. In conclusion, weekly cG250 with daily low-dose subcutaneous IL-2 is well tolerated. IL-2 does not influence cG250 biodistribution or increase HACA...
Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PETMartin H Cherk
Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
J Nucl Med 47:1921-6. 2006..These findings have direct implications in understanding the role of angiogenesis and hypoxia in NSCLC biology...
Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer modelMarcus P Kelly
Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
J Nucl Med 47:716-25. 2006....
MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptorTerrance G Johns
Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
Int J Radiat Oncol Biol Phys 78:572-8. 2010..We have previously shown that mAb 806, a novel EGFR-specific antibody, is able to inhibit the growth of U87MG.Δ2-7 glioma xenografts expressing the de2-7 EGFR and may have potential as a therapeutic...
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CTNathan Lawrentschuk
University of Melbourne Department of Surgery, Austin Hospital, Melbourne, Victoria, Australia
Urol Oncol 29:411-20. 2011....
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in miceJennifer A Westwood
Cancer Immunology Program and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, St. Andrew's Place, Melbourne, Victoria 3002, Australia
Proc Natl Acad Sci U S A 102:19051-6. 2005..This study supports the use of humanized gene-modified T cells as a potential therapy for Le(Y+) malignancies...
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studiesLawrence M Cher
Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
J Nucl Med 47:410-8. 2006..18F-FMISO PET may have a role not only in directing patients toward targeted hypoxic therapies but also in monitoring response to such therapies...
Xenografting tumour beneath the renal capsule using modern surgical equipmentNathan Lawrentschuk
Department of Surgery and Urology, Tumour Targetting Laboratory, Austin Hospital, Heidelberg, Vic, Australia
Eur Surg Res 38:340-6. 2006..We report on a novel method for human renal tumour transplants using an automated biopsy gun to obtain tumour tissue and an epidural needle with introducer to easily deploy the grafts under the renal capsule...
Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanomaAndrew M Scott
Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Victoria, 3084, Australia
Cancer Immun 5:3. 2005..The favourable immune properties of KM871, combined with this preliminary clinical data, indicate that KM871 has potential for the treatment of metastatic melanoma...
The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerizationTerrance G Johns
Oncogenic Signalling Laboratory and Tumor Targeting Program, Ludwig Institute for Cancer Research, Melbourne Centre, Austin Hospital, Heidelberg, Melbourne, Australia
Clin Cancer Res 13:1911-25. 2007..Factors affecting the efficacy of therapeutic monoclonal antibodies (mAb) directed to the epidermal growth factor receptor (EGFR) remain relatively unknown, especially in glioma...
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong
Ludwig Institute for Cancer Research, Melbourne, Australia
Clin Cancer Res 11:4818-26. 2005..CONCLUSION: Radioimmunotherapy using 131I-huA33 shows promise in targeting colorectal tumors, and is deliverable at a maximum tolerated dose of 40 mCi/m2. Further studies of 131I-huA33 in combination with chemotherapy are planned...
The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptorTerrance G Johns
Ludwig Institute for Cancer Research, Tumour Targeting Program, Austin Hospital, Heidelberg, Australia
FASEB J 19:780-2. 2005..As our observations are likely to apply to other receptors overexpressed in cancer, they suggest a strategy for developing antitumor antibodies even when the target receptor is expressed in normal tissue...
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478Terrance G Johns
Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg 3084, Australia
Proc Natl Acad Sci U S A 100:15871-6. 2003..These results establish the antitumor efficacy of the EGFR inhibitor AG1478 and provide a rationale for its clinical evaluation in combination with both chemotherapy and other EGFR therapeutics...
The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFRRodney B Luwor
Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin Hospital, Heidelberg 3084, Australia
Oncogene 23:6095-104. 2004..This observation is directly relevant to glioma where de2-7 and wt EGFR appear to be coexpressed. Thus, expression of de2-7 EGFR in BaF/3 cells provides an in vitro model for evaluating the signalling pathways activated by this receptor...
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomographyNathan Lawrentschuk
Department of Surgery, University of Melbourne, Victoria, Australia
BJU Int 96:540-6. 2005..5 mmHg. Further direct studies of renal tumour oxygenation combined with therapies directed towards hypoxia may allow a better understanding of the relationship between 18F-FMISO results and the biological significance of hypoxia in RCC...
Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationshipNathan Lawrentschuk
Department of Surgery, University of Melbourne, Australia
BJU Int 97:916-22. 2006
Hypoxia positron emission tomography imaging with 18f-fluoromisonidazoleSze Ting Lee
Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Semin Nucl Med 37:451-61. 2007..This review discusses the relevance and biology of hypoxia in cells and organ systems, and reviews the laboratory and clinical applications of (18)F-FMISO in oncology and noncancer disease states...
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancerAndrew J Weickhardt
Ludwig Institute for Cancer Research, Australia
J Clin Oncol 30:1505-12. 2012..This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC)...
Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871Zhanqi Liu
Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Heidelberg, Victoria, 3084, Australia
Cancer Immun 2:13. 2002..Furthermore, ADCC was significantly reduced using NK-depleted PBMCs. These results suggest combining IL-2 or IL-12 with KM871 may enhance KM871 immune-mediated cell killing in patients with metastatic melanoma...
Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft modelKiki Tahtis
Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin, Victoria 3084, Australia
Mol Cancer Ther 2:729-37. 2003....
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinasesVinochani Pillay
Ludwig Institute for Cancer Research, Heidelberg, Victoria 3084, Australia
Neoplasia 11:448-58, 2 p following 458. 2009..Consequently, inhibition of a dominant oncogene by targeted therapy can alter the hierarchy of RTKs resulting in rapid therapeutic resistance...
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinomaIan D Davis
Ludwig Institute for Cancer Research, Victoria, Australia
Cancer Immun 7:13. 2007..In conclusion, repeated intravenous doses of up to 50 mg/m(2) of cG250 are safe. Furthermore cG250 has a long half-life and targets clear cell RCC effectively...
Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagentsChristopher Vearing
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
Cancer Res 65:6745-54. 2005..These findings show the biological importance of EphA3/ephrin-A5 interactions and that ephrin-A5 and IIIA4 have great potential as tumor targeting reagents...
Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-METSameer A Greenall
Oncogenic Signaling Laboratory, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia
PLoS ONE 7:e34658. 2012....
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancersRebecca A Herbertson
Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
Clin Cancer Res 15:6709-15. 2009..This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Le(y)) antibody conjugated with calicheamicin in patients with advanced cancers expressing the Le(y) antigen...
Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analysesZhanqi Liu
Tumor Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Tumor Biology Branch, Austin and Repatriation Medical Centre, 145 164 Studley Road, Heidelberg, Victoria 3084, Australia
Hybrid Hybridomics 22:219-28. 2003....
Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancerKelvin K Yap
Centre for PET, University of Melbourne, Austin Hospital Heidelberg, Victoria, 3084, Australia
Eur J Nucl Med Mol Imaging 32:1033-40. 2005..These cost savings remain robust over a wide range of disease prevalence and FDG-PET costs...
Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolismAnna N Cvrljevic
Tumour Targeting Program, Ludwig Institute for Cancer Research, Heidelberg, Victoria 3084, Australia
J Cell Sci 124:2938-50. 2011..Thus, the mitochondrial localisation of de2-7EGFR contributes to its tumorigenicity and might help to explain its resistance to some EGFR-targeted therapeutics...
Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancerAnthony Hannah
Centre for Positron Emission Tomography, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
Ann Surg 236:208-17. 2002..To prospectively evaluate the use of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in the initial staging of squamous cell head and neck carcinoma...
Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalizationHui K Gan
Oncogenic Signalling Laboratory, Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Australia
J Cell Mol Med 13:3993-4001. 2009..Given the increase in VEGF, we combined mAb 806 with bevacizumab in vivo, resulting in additive activity...
Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomersNoga Kozer
Ludwig Institute for Cancer Research, Melbourne Parkville Branch, Royal Melbourne Hospital, Victoria 3050, Australia
Biochemistry 50:3581-90. 2011..The results reveal new modes of receptor-antibody interactions for EGFR and de2-7-EGFR...
Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapyJoe H Chang
Radiation Oncology Centre, Austin Health, Victoria, Australia
Radiother Oncol 99:187-92. 2011..To evaluate the accuracy of (11)C-choline PET scans in defining dominant intraprostatic lesions (DILs) for radiotherapy target volume definition...
Synthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957Uwe Ackermann
Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia
Nucl Med Biol 32:323-8. 2005..3+/-2.1% (n=3; not decay corrected) and an average specific radioactivity of 40 GBq/micromol (1.1 Ci/micromol) at the end of synthesis. The total synthesis time from EOB including HPLC purification and formulation was 45 min...
Positron emission tomography and molecular imaging of the prostate: an updateNathan Lawrentschuk
Department of Surgery, University of Melbourne, Australia
BJU Int 97:923-31. 2006
Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsyGlenn P Ollenberger
Department of Nuclear Medicine and Centre for PET, University of Melbourne, Melbourne, Australia
Eur J Nucl Med Mol Imaging 32:1311-6. 2005..In the future, analysis of FDG PET data in specific subpopulations of children with refractory epilepsy may lead to novel insights regarding aetiology...
Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodiesPaul Mitchell
Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Melbourne, Victoria, Australia
J Nucl Med 44:1105-12. 2003....
Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanomaMarion T Harris
Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
Mol Imaging Biol 7:304-8. 2005..CONCLUSION: FDG-PET has an important role in guiding the management of patients with advanced melanoma, particularly when surgery is contemplated...
Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicityZhanqi Liu
Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
Cancer Immunol Immunother 51:171-7. 2002....
High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancerArun Azad
Ludwig Institute Oncology Unit, Austin Health, Heidelberg, Australia
Mol Imaging Biol 12:443-51. 2010..We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC)...
Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practiceNathan Lawrentschuk
University of Melbourne, Department of Surgery, Victoria, Australia
Int J Urol 14:89-95. 2007..This article summarizes the current diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer with particular reference to radionuclide bone scintigraphy and positron emission tomography...
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancerDavid S Binns
The Peter MacCallum Cancer Centre, Melbourne, Australia
Eur J Nucl Med Mol Imaging 38:642-50. 2011..Molecular imaging assessments, including changes in (18)F-deoxyglucose (FDG) or (18)F-deoxythymidine (FLT) uptake by positron emission tomography (PET), may provide earlier, more robust evaluation of treatment efficacy...
Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorderJames S Olver
Department of Psychiatry, University of Melbourne, Heidelberg, Victoria, Australia
Psychiatry Res 183:85-8. 2010..These findings suggest mesocortical dopamine inputs via D(1) receptors may play a role in the aetiology of OCD...
Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapyHui K Gan
Joint Austin Ludwig Medical Oncology Unit, Austin Hospital, Australia
Cancer Res 72:2924-30. 2012..This concept of conformational epitope targeting by antibodies reflects an underlying interplay between the structure and biology of different conformational forms of the EGFR family...
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serumJennifer A Westwood
Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria 3002, Australia
J Immunother 32:292-301. 2009....
Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancerElizabeth Yuriev
Department of Medicinal Chemistry, Victorian College of Pharmacy, Monash University, Victoria, Australia
Immunol Cell Biol 83:709-17. 2005....
A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibodyWilliam Farrugia
Centre for Immunology, Burnet Institute, Melbourne, Victoria, Australia
PLoS ONE 4:e7777. 2009..A humanized Le(y)-specific antibody (hu3S193) has shown encouraging safety, pharmacokinetic and tumor-targeting properties in recently completed Phase I clinical trials...
Immuno-PET for tumor targetingFook T Lee
Tumour Targeting Program, Ludwig Institute for Cancer Research, Centre for PET, Austin Hospital, 145-163 Studley Road, Heidelberg, Victoria 3084, Australia
J Nucl Med 44:1282-3. 2003
Therapeutic targeting of the epidermal growth factor receptor in human cancerNathalie S Dhomen
Ludwig Institute for Cancer Research, Melbourne, Australia
Crit Rev Oncog 17:31-50. 2012....
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis
Ludwig Institute for Cancer Research, Melbourne 3084, Australia
Proc Natl Acad Sci U S A 101:10697-702. 2004..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR geneTerrance G Johns
Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne, Australia
Int J Cancer 98:398-408. 2002..Thus, MAb 806 can be used to target tumor cells containing amplification of the EGFR gene or de2-7 EGFR but does not bind to the wild type EGFR when expressed on the cell surface...
CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptorFrancesca Walker
Ludwig Institute for Cancer Research, PO Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
J Biol Chem 279:22387-98. 2004....
Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigensPaul A Ramsland
Structural Immunology Laboratory, Austin Research Institute, Heidelberg, VIC 3084, Australia
J Mol Biol 340:809-18. 2004..Closely related blood-group determinants (Le(a) and Le(b)) cannot enter the specificity pocket, making the Le(y) antibodies promising candidates for immunotherapy of epithelial cancer...
Functional imaging of intratumoral hypoxiaSerene S Foo
Ludwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Victoria, Australia
Mol Imaging Biol 6:291-305. 2004....
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug eliminationMichael Michael
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia
J Clin Oncol 24:4228-35. 2006....
Radiation dose to PET technologists and strategies to lower occupational exposureFiona O Roberts
Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia
J Nucl Med Technol 33:44-7. 2005..01] and 3.4 microSv [P = 0.03], respectively). CONCLUSION: The radiation doses currently received by technologists working in PET are within accepted occupational health guidelines, but improved shielding can further reduce the dose...
Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO)Henri J Tochon-Danguy
Centre for PET, Austin and Repatriation Medical Centre, 3084, Melbourne, Victoria, Australia
Nucl Med Biol 29:191-7. 2002..Quantitation of uptake of FMISO showed a tumor/brain ratio of 1.9 and a tumor/blood ratio of 2.6 at 2 hours post injection...
Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomographySerene S Foo
Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Victoria, Australia
Australas Radiol 48:214-6. 2004..Assessment of glucose metabolism with FDG PET might represent a more powerful tool to detect bone metastases in lung cancer compared with conventional bone scans...
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogelShinichi Kageyama
Department of Immuno Gene Therapy, Mie University Graduate School of Medicine, 2 174 Edobashi, Tsu, Mie 514 8507, Japan
Cancer Sci 99:601-7. 2008..Our results indicate that CHP-HER2 induced HER2-specific humoral responses in patients with HER2-expressing tumors and that GM-CSF seems to accelerate the responses...
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancerAndrew M Scott
Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and Repatriation Medical Centre, 3084 Australia
Clin Cancer Res 9:1639-47. 2003....
Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion proteinStefan Bauer
Medical Department I, , Homburg/Saar, Germany
J Immunol 172:3930-9. 2004..These data warrant transfer of the anti-FAP-TNF immunocytokine into clinical trials for the treatment of FAP-positive tumors...
Radioimmunotherapy of prostate cancer: does tumor size matter?Andrew M Scott
J Clin Oncol 23:4567-9. 2005
Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'David J Macfarlane
Department of Nuclear Medicine, Royal Brisbane and Women s Hospital, Australia
Eur J Nucl Med Mol Imaging 33:648-56. 2006..The purpose of this study was to evaluate the safety, pharmacokinetics and dosimetry of four increasing doses of (99m)Tc-DI-80B3 Fab' in healthy volunteers...
Novel imaging techniques in melanomaRichard Essner
Department of Surgical Oncology and Molecular Therapeutics, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
Surg Oncol Clin N Am 15:253-83. 2006..In translational research, [18F]fluorodeoxyglucose probes have been designed to optimize the detection of melanoma tumor sites in vivo...
Role of nuclear medicine in the management of cutaneous malignant melanomaTarik Z Belhocine
Department of Diagnostic Radiology and Nuclear Medicine, St Joseph s Hospital, London, Ontario, Canada
J Nucl Med 47:957-67. 2006..In this article, we review the role of nuclear medicine in the assessment of malignant melanoma...
A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinomaJunichi Sakamoto
Department of Epidemiological and Clinical Research Information Management, Kyoto University, Kyoto 606 8501, Japan
Cancer Sci 97:1248-54. 2006....
HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulanShigehisa Kitano
Department of Medical Oncology and Immunology, Mie University Graduate School of Medicine, Japan
Clin Cancer Res 12:7397-405. 2006..CONCLUSIONS: CHP-HER2 vaccine was safe and induced HER2-specific CD8(+) and/or CD4(+) T-cell immune responses...
Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agentRodney J Hicks
Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett St, Melbourne 8006, Australia
Eur J Nucl Med Mol Imaging 32:1384-91. 2005..The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy...
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levelsLee M Krug
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
J Thorac Oncol 2:947-52. 2007..A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies...
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptorAchim A Jungbluth
Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 100:639-44. 2003..Our study also indicates that DeltaEGFR is restricted to glioblastoma, in contrast to other reports that this mutation is found in tumors outside the brain...
Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibodyBarbara E Power
CSIRO Health Sciences and Nutrition, Parkville, Victoria 3052, Australia
Protein Sci 12:734-47. 2003....
